ライフサイエンスコーパス: epicutaneous

1 s into draining lymph nodes (LNs) 24 h after epicutaneous administration of FITC in naive mice was si

2 immunization with Alum-adsorbed rBet v 1 and epicutaneous administration of rBet v 1 with PDS in comb

3 Inhibition of Met signaling by single-dose epicutaneous administration of the Met kinase-specific i

4 Epicutaneous allergen administration using a patch may b

5 ll versus wild-type BALB/c mice following an epicutaneous allergen-sensitization/challenge model that

6 Recently, epicutaneous allergen-specific immunotherapy (EPIT) has

7 Epicutaneous allergen-specific immunotherapy (EPIT) is p

8 The results of our third trial on epicutaneous allergen-specific immunotherapy (EPIT) will

9 Epicutaneous allergen-specific immunotherapy (EPIT) with

10 enetically engineered mice were subjected to epicutaneous antigen sensitization and the development o

11 ng ovalbumin or Aspergillus fumigatus as the epicutaneous antigen.

12 and the associated lymphoid tissue following epicutaneous application and intracutaneous injection of

13 This defect was tissue-specific, and epicutaneous application of antigen generated a populati

14 les were collected 6, 24, and 48 hours after epicutaneous application of Dermatophagoides farinae hou

15 Epicutaneous application of dinitrothiocyanobenzene (DNT

16 ation into humans was also accomplished with epicutaneous application of fingolimod resolving histami

17 Notably, both intradermal injection and epicutaneous application of lauric acid effectively decr

18 sebaceous glands of mouse ear skin after an epicutaneous application of OA, the most hBD-2-inducible

19 DCs in the generation of immune responses to epicutaneous application of ovalbumin and during contact

20 Epicutaneous application of protein antigen in the prese

21 zed into three groups: (1) models induced by epicutaneous application of sensitizers; (2) transgenic

22 sensitivity responses induced in mice by the epicutaneous application of the haptens FITC and oxazolo

23 eradicated by a simple vaccination strategy: epicutaneous application of the related orthopoxvirus va

24 described an animal model in which repeated epicutaneous applications of a house dust mite extract a

25 o a physiological skin self-Ag desmoglein-3, epicutaneous applications of desmoglein-3 induced tolera

26 ice exhibited an exaggerated Th2 response to epicutaneous but not to intraperitoneal sensitization wi

27 responsible for protective immunity against epicutaneous Candida infections are incompletely charact

28 We infected mice via epicutaneous challenge of the skin on the outer ear pinn

29 d as an increase in ear thickness 24 h after epicutaneous challenge, was significantly enhanced in ma

30 The study of nanotechnology for epicutaneous delivery of pharmaceuticals and vaccines is

31 Mucosal or epicutaneous delivery of vaccines helps target the induc

32 ontrast, IL-4(-/-) mice initially exposed to epicutaneous (e.c.) OVA mounted Th2 responses equivalent

33 ination of intense pruritus, scratching, and epicutaneous (e.c.) sensitization with allergens.

34 Allergic skin inflammation in response to epicutaneous (EC) application of ovalbumin to tape-strip

35 Epicutaneous (EC) immunization of mice with ovalbumin (O

36 Herein, we describe a murine model of epicutaneous (EC) sensitization to the protein allergen,

37 ouse model of allergic dermatitis induced by epicutaneous (EC) sensitization with OVA on tape-strippe

38 reviously unknown pathway by which S. aureus epicutaneous exposure promotes skin inflammation involvi

39 ese findings provide the first evidence that epicutaneous exposure to allergens potently primes for E

40 We aimed to test the hypothesis that epicutaneous exposure to antigen primes for subsequent r

41 d protein in human skin biopsy samples after epicutaneous exposure to liquid-phase HDI, although the

42 have reported that Th2 responses induced by epicutaneous exposure to OVA are IL-4 independent.

43 Further, after 7 days of epicutaneous exposure to wild-type S. aureus, but not S.

44 ependent cellular immune response induced by epicutaneous hapten.

45 Epicutaneous HDM application led to TH2 sensitization an

46 We show here that epicutaneous immunization (ECi) with the immunodominant

47 BALB/c mice received epicutaneous immunization (EPI) with recombinant Bet v 1

48 Allergic skin inflammation elicited by epicutaneous immunization of mice with ovalbumin (OVA),

49 Epicutaneous immunization of T cell receptor (TCR) trans

50 The study also suggests that epicutaneous immunization or immunotherapy can be improv

51 spare other Langerin(+) DC do not impair the epicutaneous immunization response to OVA.

52 Epicutaneous immunization was performed by applying a sk

53 Epicutaneous immunization with CT does not require engag

54 Finally, the results suggest that epicutaneous immunization with OVA and CpG decreases the

55 Epicutaneous immunization with OVA and CpG reduces the p

56 C elimination reduced the T cell response to epicutaneous immunization with OVA protein Ag.

57 s as well as IL-10 cytokine production after epicutaneous immunization with ovalbumin (OVA).

58 Epicutaneous immunization with rBet v 1 plus R848 induce

59 g-specific CD4 and CD8 T cell responses upon epicutaneous immunization, but could not detect a role i

60 antigen delivery through the unbroken skin (epicutaneous immunization, EPI) has immediate relevance

61 ize the regulatory cells that are induced by epicutaneous immunization.

62 We evaluated peanut epicutaneous immunotherapy (EPIT) by using Viaskin Peanu

63 nsitized piglets to evaluate the efficacy of epicutaneous immunotherapy (EPIT) for its treatment.

64 ficacy and mechanism of tolerance induced by epicutaneous immunotherapy (EPIT) in a model of food-ind

65 We sought to evaluate the effect of early epicutaneous immunotherapy (EPIT) on further sensitizati

66 of this study was to compare the efficacy of epicutaneous immunotherapy (EPIT) to sublingual immunoth

67 R848 could be a promising adjuvant in epicutaneous immunotherapy for birch pollen-induced alle

68 Epicutaneous immunotherapy is safe and efficacious in a

69 Epicutaneous immunotherapy may have potential for treati

70 Recently, the safety and early efficacy of epicutaneous immunotherapy were also demonstrated in pat

71 t, and R848 (resiquimod), a TLR7 agonist, in epicutaneous immunotherapy with Bet v 1, the major birch

72 ical trials, including oral, sublingual, and epicutaneous immunotherapy, immunotherapy combined with

73 ublingual immunotherapy, and, more recently, epicutaneous immunotherapy.

74 or forms of treatment: oral, sublingual, and epicutaneous immunotherapy.

75 Using a murine epicutaneous infection model, we found that S. aureus-ex

76 CD4 and CD8 T cells after needle injection, epicutaneous infection, or vaginal mucosal herpes simple

77 cells after vaginal infection compared with epicutaneous infection.

78 n immunotherapy have been studied, including epicutaneous, intralymphatic, intranasal, and oral immun

79 monella typhimurium and perish shortly after epicutaneous or orogastric infection respectively.

80 d allergies; these involve oral, sublingual, epicutaneous, or subcutaneous administration of small am

81 study, we show that Th2 responses induced by epicutaneous OVA exposure (including lung inflammatory r

82 iased allergic skin inflammation elicited by epicutaneous ovalbumin (OVA) sensitization exhibited lar

83 atricians and perhaps more widespread use of epicutaneous patch testing.

84 In mice, this epicutaneous peanut exposure induced sensitization to th

85 omly assigned patients (1:1:1:1) received an epicutaneous peanut patch containing 50 mug (n = 53), 10

86 esponse to both contact hypersensitivity and epicutaneous protein immunization, and resulted in a dra

87 We show that exposure to antigen via the epicutaneous route primes for marked eosinophilic inflam

88 Herein, epicutaneous S. aureus exposure to mouse skin promoted M

89 IL-17-mediated skin inflammatory response to epicutaneous S. aureus infection.

90 female mice with ovalbumin (OVA) followed by epicutaneous sensitization and oral challenge of their o

91 vant-free model of food allergy generated by epicutaneous sensitization and reactions triggered by or

92 ulation, and promotes oral anaphylaxis after epicutaneous sensitization by targeting MCs.

93 In an epicutaneous sensitization model, the response to recomb

94 ersa TLR4 expression rather protects against epicutaneous sensitization to house dust mite allergen D

95 Epicutaneous sensitization was found to be driven by 2 v

96 tested in a murine model of EoE elicited by epicutaneous sensitization with Aspergillus fumigatus pr

97 We sought to test the hypothesis that epicutaneous sensitization with food antigen predisposes

98 DC in response to various stimuli, including epicutaneous sensitization with hapten and skin infectio

99 se model of allergic inflammation induced by epicutaneous sensitization with OVA.

100 tly described murine model of AD elicited by epicutaneous sensitization with ovalbumin (OVA) (1) and

101 lergic skin inflammation induced by repeated epicutaneous sensitization with ovalbumin (OVA), and cha

102 gal3(-/-)) and wild-type (gal3(+/+)) mice to epicutaneous sensitization with ovalbumin (OVA).

103 Epicutaneous sensitization with ovalbumin of WT mice but

104 and anaphylaxis that involved either oral or epicutaneous sensitization.

105 cretion of Th2 cytokines by splenocytes from epicutaneous sensitized TSLPR(-/-) mice in response to O

106 d skin thickening and collagen deposition in epicutaneous-sensitized skin of DeltadblGATA recipients.

107 Liu et al. (2017) define a pathway by which epicutaneous Staphylococcus aureus promotes skin inflamm

108 re the allergen are not found by history and epicutaneous testing is required.

109 ct, and identifies novel mechanisms by which epicutaneous tolerance can suppress food-induced anaphyl

110 We sought to determine whether epicutaneous treatment with antigen in the presence of a

111 Epicutaneous treatment with vinblastine caused a reducti

112 Epicutaneous vaccination has gained increasing interest

113 One major challenge to epicutaneous vaccination is the barrier function of the

114 n C fragment when administered as a nasal or epicutaneous vaccine.

115 ractions with virus-infected cells following epicutaneous vaccinia virus (VV) infection of mice.

116 Epicutaneous vaccinia virus (VV) infection, mimicking hu

117 g chemokines, which accelerates clearance of epicutaneous vaccinia virus infection.